Alnylam Taps Generative AI And Nordic Expansion As Market Lags Targets
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.
-
Alnylam Pharmaceuticals (NasdaqGS:ALNY) has entered a collaboration with Inceptive Nucleics to apply generative AI models to its RNAi research and development.
-
The company has also expanded its commercial partnership with GENESIS Pharma to cover the Nordic countries, extending the reach of its RNAi therapies in Europe.
Alnylam shares most recently closed at $282.85, with the stock down 29.3% year to date and down 8.2% over the past year. Over a 3 year period the stock is up 40.3%, and over 5 years it is up 59.9%, which gives useful context for assessing how these new moves fit into a longer performance track record.
For investors watching RNA based drug developers, the AI collaboration and the expanded GENESIS Pharma agreement add fresh pieces to the story around Alnylam’s research productivity and global reach. How effectively the company integrates generative AI into its R&D and executes in the Nordics will likely be key factors to monitor when reviewing the thesis on NasdaqGS:ALNY.
Wall Street’s queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab’s valuation page.
4 things going right for Alnylam Pharmaceuticals that this headline doesn’t cover.
Quick Assessment
-
✅ Price vs Analyst Target: At US$282.85, the stock trades about 35% below the US$438.52 consensus target.
-
✅ Simply Wall St Valuation: Shares are described as trading 54.6% below an estimate of fair value, which flags a valuation gap.
-
❌ Recent Momentum: The stock is down 1.4% over the last 30 days, so price has not yet reflected this news.
There’s only one way to know the right time to buy, sell or hold Alnylam Pharmaceuticals. Head to Simply Wall St’s company report for the latest analysis of Alnylam Pharmaceuticals’s Fair Value.
Key Considerations
-
📊 The AI partnership with Inceptive Nucleics and Nordic expansion with GENESIS Pharma both relate to Alnylam’s focus on R&D productivity and European revenue potential.
-
📊 Monitor how management quantifies AI driven R&D efficiency, the performance of new Nordic launches, and whether these appear in revenue, margin, and EPS trends.
-
⚠️ Execution risk is central here. If AI integration or new country rollouts are slower or more costly than planned, that could weigh on returns even with supportive analyst targets.
